Home » Topics » BioWorld Science

BioWorld Science
RSS

Tyvyt approved in China for the treatment of Hodgkin's lymphoma

Dec. 27, 2018

ROMK inhibitors reported in Bristol-Myers Squibb patent

Dec. 27, 2018

Sunshine Lake Pharma reports agents for the treatment of HBV infections

Dec. 27, 2018

Positive data presented from dose-escalation portion of phase I study of TRC-105

Dec. 27, 2018

AbbVie licenses Lupin's MALT1 inhibitor program

Dec. 27, 2018

Mitophagy findings may offer new PD treatment promise

Dec. 27, 2018

TRACON Pharmaceuticals submits IND application for TJ-4309

Dec. 27, 2018

MEI Pharma initiates phase II study of ME-401 in follicular lymphoma

Dec. 27, 2018

Shenzhen Salubris Pharmaceuticals describes DPP-IV inhibitors for diabetes

Dec. 27, 2018

NantBioScience reports high-affinity nerve growth factor receptor inhibitors

Dec. 27, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...